Epstein-Barr virus-related immune targets (EBV immune targets)

Epstein-Barr virus-related immune targets refer to a diverse set of proteins encoded by the Epstein-Barr virus (EBV) that play pivotal roles in the viral life cycle and are recognized by the host's immune system [1, 4]. These targets include latent proteins such as Epstein-Barr nuclear antigen 1 (EBNA1), which ensures the persistence of the viral episome, and latent membrane proteins (LMP1 and LMP2), which mimic cellular signaling molecules to promote B-cell survival and proliferation [1, 4]. Additionally, lytic cycle proteins and surface glycoproteins like gp350 and gp42 are essential for viral entry and are primary focuses for vaccine and monoclonal antibody development [2, 3, 4]. These targets are critically involved in the development of EBV-associated malignancies, such as Burkitt lymphoma, Hodgkin lymphoma, and nasopharyngeal carcinoma, and have been linked to autoimmune conditions like multiple sclerosis [1, 2, 7]. Therapeutic approaches targeting these molecules include EBV-specific T-cell therapies, such as tabelecleucel, which provide an exogenous immune response against infected cells, and various antiviral agents that inhibit viral replication [1, 5]. Small molecule inhibitors targeting viral kinases or host proteins like PARP1 are also being explored to disrupt viral genome maintenance and induce cell death in EBV-positive cells [5, 6]. Monitoring EBV DNA load and specific antibody titers serves as a key biomarker strategy for assessing disease progression and therapeutic efficacy [4, 5].

Other names

EBV antigensEpstein-Barr virus proteinsEBV latent antigensEBV lytic antigensEBV-encoded proteins

Therapeutic strategies targeting these molecules include T-cell mediated cytotoxicity against EBV-infected cells, inhibition of viral DNA replication by nucleoside analogues, and neutralization of viral entry proteins by monoclonal antibodies [1, 2, 5].